Answer
Enspryng (satralizumab) is contraindicated in patients with hypersensitivity to satralizumab or any excipient listed in section 6.1.
Sources for this answer
- Enspryng 120 mg solution for injection in pre-filled syringeRoche Products Limited · emc · SmPC §4.3 Contraindications · Version 3Document updated
Sources checked